{"nct_id":"NCT02955212","title":"A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)","status":"COMPLETED","status_verified_date":"2021-08","start_date":"2018-01-03","start_date_type":"ACTUAL","primary_completion_date":"2019-08-14","primary_completion_date_type":"ACTUAL","completion_date":"2020-09-03","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["ABBV"]}